Document Detail

Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction.
MedLine Citation:
PMID:  19072878     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Several cardiac biomarkers have been shown to have predictive values for the development of cardiovascular disease and clinical outcome after events, and are now broadly used by clinicians. Little is known about the utility of these biomarker values on admission in ST-elevation myocardial infarction (STEMI) cases of primary drug-eluting stent (DES) implantation and intense medical therapy. HYPOTHESIS: Because little is known about the utility of these biomarkers on admission in ST-elevation myocardial infarction (STEMI) in cases primary drug-eluting stent (DES) implantation and intense medical therapy, we evaluated clinical outcomes. METHODS: We enrolled 207 consecutive STEMI patients treated with primary stenting (mean age, 57.3 +/- 12.0 y). We evaluated the association between B-type natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) on admission, and death, reinfarction, and new or worsening congestive heart failure (CHF) through 1 y. RESULTS: In backward-elimination models including all biomarkers, only the cTnI level was retained as a predictor of 1-y CHF (odds ratio [OR]: 1.017, 95% confidence interval [CI]: 1.001-1.034, p = 0.039). There were no predictors in terms of 1-y death, reinfarction, and composite endpoint. When we applied a simple score system, in which patients were categorized on the basis of the number of elevated biomarkers, the 1-y risks of death (p = 0.600), reinfarction (p = 0.185), and composite endpoint (p = 0.620) did not increase in proportion to the number of elevated biomarkers on admission. One-y CHF only tended to increase according to the number of elevated biomarkers (p = 0.067). CONCLUSIONS: The use of cardiac biomarkers on admission, in each or in combination, had only a minimal impact for the prediction of long-term cardiovascular events after primary stenting in STEMI patients.
Young-Hoon Jeong; Seung-Whan Lee; Cheol Whan Lee; Myeong-Ki Hong; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park; Duk-Woo Park; Young-Hak Kim
Related Documents :
18261678 - "off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents.
17258088 - Impact of stable versus unstable coronary artery disease on 1-year outcome in elective ...
16293318 - Stenting for bilateral congenital choanal atresia--a new technique.
8800018 - Reduction in angioplasty complications after the introduction of coronary stents: resul...
19317708 - A meta-analysis of the utility of c-reactive protein in predicting early, intermediate-...
21350828 - Evaluation of right ventricular function.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical cardiology     Volume:  31     ISSN:  0160-9289     ISO Abbreviation:  Clin Cardiol     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-25     Completed Date:  2009-02-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  572-9     Citation Subset:  IM    
Copyright Information:
(c) 2008 Wiley Periodicals, Inc.
Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angioplasty, Transluminal, Percutaneous Coronary*
Biological Markers / blood
C-Reactive Protein / analysis*
Middle Aged
Multivariate Analysis
Myocardial Infarction / blood*,  therapy*
Natriuretic Peptide, Brain / blood*
Troponin I / blood*
Young Adult
Reg. No./Substance:
0/Biological Markers; 0/Troponin I; 114471-18-0/Natriuretic Peptide, Brain; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk of heart failure due to a combination of mild mitral regurgitation and impaired distensibility ...
Next Document:  Effects of levosimendan on left atrial functions in patients with ischemic heart failure.